| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | CDW1; DCAF2; Dtl; L2DTL; RAMP |
| Entrez GeneID | 51514 |
| WB Predicted band size | Calculated MW: 79 kDa; Observed MW: 79 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Recombinant protein of human CDT2 |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是关于CDT2抗体的3篇参考文献及其摘要内容，涵盖其功能及抗体应用：
---
1. **文献名称**: *CUL4-DDB1-CDT2 E3 ligase regulates the molecular clock activity by promoting ubiquitination-dependent degradation of the CRY1 protein*
**作者**: Higa, L.A., Yang, X., Zheng, J., Banks, D., Wu, M., & Zhang, H.
**摘要**: 本研究揭示了CRL4-CDT2复合体通过泛素化降解CRY1蛋白调控生物钟的机制。作者利用CDT2特异性抗体进行免疫沉淀和Western blot分析，证明CDT2在DNA损伤后招募到染色质上，并参与靶蛋白的降解，为细胞周期调控提供了新见解。
---
2. **文献名称**: *The DDB1-CDT2 E3 ligase regulates cell cycle-dependent degradation of Cdt1 via Proliferating Cell Nuclear Antigen (PCNA)-binding*
**作者**: Jin, J., Arias, E.E., Chen, J., Harper, J.W., & Walter, J.C.
**摘要**: 该研究克隆了DTL/CDT2基因，并发现其编码蛋白通过与PCNA结合调控CDT1的泛素化降解。作者开发了特异性CDT2抗体，证实其在S期和DNA损伤后对CDT1的降解起关键作用，为理解复制许可调控提供了实验基础。
---
3. **文献名称**: *CRL4-CDT2 ubiquitin ligase regulates re-replication by degrading geminin and Cdt1*
**作者**: Michishita, M., Morimoto, A., Ishii, T., Komori, H., Shiomi, Y., & Nishitani, H.
**摘要**: 通过使用CDT2抗体进行免疫荧光和染色质结合实验，本研究证明CRL4-CDT2复合体通过降解geminin和Cdt1抑制DNA再复制。研究强调了CDT2在维持基因组稳定性中的核心作用，并展示了抗体在亚细胞定位分析中的应用。
---
**备注**：若需更多实验性研究，可补充以下综述(非直接抗体应用，但提供背景)：
4. **文献名称**: *CRL4^Cdt2: Master coordinator of cell cycle progression and genome stability*
**作者**: Abbas, T., & Dutta, A.
**摘要**: 该综述系统总结了CRL4-CDT2复合体在细胞周期调控、DNA修复及癌症中的作用机制，强调了CDT2作为底物识别因子的功能，为后续抗体开发及功能研究提供了理论框架。
---
以上文献均涉及CDT2抗体的实验应用(如Western blot、免疫沉淀等)，适用于研究其分子机制及功能验证。
The CDT2 antibody is a crucial tool in studying the biological role of CDT2 (also known as DCAF2 or L2DTL), a substrate recognition subunit of the CRL4 (Cullin-RING E3 ubiquitin ligase 4) complex. CDT2 plays a pivotal role in ubiquitin-mediated proteolysis, regulating cell cycle progression, DNA replication, and damage response. It specifically targets proteins like p21. SET8. and Cdt1 for degradation via the ubiquitin-proteasome system, ensuring proper S-phase progression and genomic stability. Dysregulation of CDT2 is linked to replication stress, aberrant cell cycle control, and carcinogenesis, making it a focus in cancer research.
The CDT2 antibody is widely used in Western blotting, immunofluorescence, and immunoprecipitation to detect CDT2 expression levels, subcellular localization, and interactions in various experimental models. Its application helps elucidate mechanisms underlying DNA repair pathways, replication licensing, and tumorigenesis. Studies employing this antibody have highlighted CDT2's overexpression in certain cancers, correlating with poor prognosis and chemoresistance. Additionally, it aids in exploring therapeutic strategies targeting the CRL4-CDT2 axis to disrupt cancer cell survival. As research advances, the CDT2 antibody remains integral to understanding cellular homeostasis and developing precision oncology approaches.
×
